For instance, in EGFR-mutant NSCLC harboring MET amplification as ARM to EGFR TKI, dual inhibition of EGFR and MET with the combination of osimertinib and savolitinib, respectively, provided promising results with an acceptable risk-benefit profile and encouraging antitumor activity [31]. Here, EGFR is linked to non-small cell lung carcinoma.